In 2017, we received funding from CIHR’s Partnership for Health Systems Improvement initiative for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) collaboration. This collaboration will develop a framework for the generation and use of Real World Evidence (RWE) for cancer drug funding decisions in Canada.
The CanREValue collaboration brings together key stakeholders including ARCC, CADTH/ pCODR, CAPCA, Health Canada, INESSS, Ministries/departments of Health, pCPA, PMPRB, and provincial cancer agencies from across Canada. By providing a platform for stakeholders to discuss their needs and existing evidence gaps, the CanREValue collaboration will enable knowledge exchange, and address policy relevant research questions.
Contact us: CanREValue@cc-arcc.ca
Article: A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
New Publication: Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
New Publication: Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
- Patient perspectives of Value Frameworks used to Guide Oncology Treatment DecisionsMay 1, 2021 - 12:27 pm
- Understanding British Columbia cancer patients’ experiences with virtual health before and during the COVID-19 pandemicMay 1, 2021 - 11:53 am
- Benchmarking End of Life Quality Indicators by Tumor Type & Describing models of palliative care across CanadaApril 1, 2021 - 8:56 am
- Evaluation of the systemic cancer therapy volume-outcome association: a population-based study to inform the optimal provincial organization and delivery of systemic cancer therapyFebruary 1, 2021 - 12:20 pm